Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.

Fiche publication

Date publication

novembre 2025

Journal

Clinical genitourinary cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Reverdy T, Izarn F, Allignet B, Roubaud G, Gibson N, Teyssonneau D, Thibault C, Berthou H, Houede N, Fléchon A, Tartas S, Moinard-Butot F, Barthelemy P, Maillet D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41349225

Résumé

FGFR3 alterations are observed in 10% to 15% of patients with advanced urothelial carcinoma (UC). We aimed to clarify the prognostic and predictive value of FGFR3 alterations in patients receiving first-line platinum-based chemotherapy (PBC) for advanced urothelial carcinoma.